12]] Patients who relapse after treatment with standard therapies, including PIs and IMiDs
have poor prognoses and few treatment options available.
Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for daratumumab as a treatment for patients with multiple myeloma who are refractory to both a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD
), or who have received three or more prior lines of therapy, including a PI and an IMiD
1] Patients who are refractory to both PIs and IMiDs
have a poor prognosis, with an estimated median overall survival of nine months.
8 months) for multiple myeloma patients previously treated with IMiDs
and bortezomib who received 2 or more prior regimens," said study investigator Jesus San Miguel, MD, Director of Clinical and Translational Medicine, Clinica Universidad de Navarra, Pamplona, Spain.
REVLIMID and other IMiDs
compounds continue to be evaluated in over 75 clinical trials in a broad range of oncological conditions, both in blood cancers and solid tumors.
Pomalidomide and other IMiDs
continue to be evaluated in over 100 clinical trials.
These drugs modulate the immune system and together are called immunomodulators or IMiDs
About the ALIGN Study ALIGN (multi-country, cross section AL study to Determine patient spec I fic and G eneral beliefs towards medicatio N ) was a study of adult patients diagnosed with one of six chronic IMIDs
(RA, AS, PsA, CD, UC or PsO) who were receiving conventional therapy and/or TNF inhibitors and who were recruited by specialists at different disease severity stages.